Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: Preliminary case series

Clin Exp Allergy. 2023 Mar 16. doi: 10.1111/cea.14305. Online ahead of print.

Authors

Roselie Achten¹, Coco Dekkers¹, Daphne Bakker¹, Chantal van Luijk², Marlies de Graaf¹, Femke van Wijk³, Joke de Boer², Marjolein de Bruin-Weller¹, Judith Thijs¹

Affiliations

¹ Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, The Netherlands.
² Department of Ophthalmology, University Medical Center Utrecht, Utrecht, The Netherlands.
³ Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

PMID: 36924265
DOI: 10.1111/cea.14305

No abstract available

Keywords: atopic dermatitis; autoimmunity; basic mechanisms; dermatology; ocular allergy.

Publication types

Letter

Grant support